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Background. Neurosphere-derived cells (NC), containing neural stem cells, various progenitors and more differentiated cells,
were obtained from newborn C57/BL6 mice and infused in a murine model of focal ischemia with reperfusion to investigate if:
1) they decreased ischemic injury and restored brain function; 2) they induced changes in the environment in which they are
infused; 3) changes in brain environment consequent to transient ischemia were relevant for NC action. Methodology/
Principal Findings. NC were infused intracerebroventricularly 4 h or 7 d after 30 min middle cerebral artery occlusion. In
ischemic mice receiving cells at 4 h, impairment of open field performance was significantly improved and neuronal loss
significantly reduced 7–14 d after ischemia compared to controls and to ischemic mice receiving cells at 7 d. Infusion of murine
foetal fibroblast in the same experimental conditions was not effective. Assessment of infused cell distribution revealed that
they migrated from the ventricle to the parenchyma, progressively decreased in number but they were observable up to 14 d.
In mice receiving NC at 7 d and in sham-operated mice, few cells could be observed only at 24 h, indicating that the survival of
these cells in brain tissue relates to the ischemic environment. The mRNA expression of trophic factors such as Insulin Growth
Factor-1, Vascular Endothelial Growth Factor-A, Transforming Growth Factor-b1, Brain Derived Neurotrophic Factor and
Stromal Derived Factor21a, as well as microglia/macrophage activation, increased 24 h after NC infusion in ischemic mice
treated at 4 h compared to sham-operated and to mice receiving cells at 7 d. Conclusions/Significance. NC reduce
functional impairment and neuronal damage after ischemia/reperfusion injury. Several lines of evidence indicate that the
reciprocal interaction between NC and the ischemic environment is crucial for NC protective actions. Based on these results we
propose that a bystander control of the ischemic environment may be the mechanism used by NC to rapidly restore acutely
injured brain function.
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Changing the Ischemic Microenvironment. PLoS ONE 2(4): e373. doi:10.1371/journal.pone.0000373
INTRODUCTION
Studies focusing on restoring injured brain function through cell
transplantation have shown that cells infused by different routes or
grafted into the brain may survive and lead to improvement of the
damage observed in different brain disease models [1–4]. Cell
replacement strategies are particularly promising candidate therapies
for stroke, a condition in which a widespread loss of different cell types
occurs that in principle may benefit from exogenous stem cells
replacement of lost or damaged cells. However, while a number of
reports show the effectiveness of this strategy, others fail to show
significant results leaving many questions unresolved [3–5]. Success-
ful reports, obtained using embryonic, bone marrow, umbilical cord
or immortalized cell lines, such as NT2, demonstrated improvement
of behavioral deficits determined by ischemia (reviewed in [3–5]). In
spite of this evidence, the definition of the conditions for a successful
treatment (the best source of stem cells, their optimal concentration,
the best route of delivery, the degree of differentiation, etc…), as well
as the mechanisms by which stem cells may exert their protective
action are still largely unresolved. In principle, stem cells can act
through several possible mechanisms, i.e. stimulating the plastic
response or neural activity in the host damaged tissue, secreting
survival-promoting neurotrophic factors, restoring synaptic trans-
mitter release by providing local reinnervation, integrating into
existing neural and synaptic network and reestablishing functional
afferent and efferent connections. Presently, the lack of knowledge of
the mechanisms driving stem cell protective action is a major obstacle
to the advancement of cell replacement strategies in stroke research.
Neurospheres are free-floating heterogeneous aggregates that
contain a minority of neural stem cells together with various
progenitors and more differentiated cells. These clusters of cells,
under appropriate culture condition, are able to produce neurons,
astrocytes and oligodendrocytes [6,7]. Neurosphere-derived cells
(NC) have been successfully used in models of brain injury such as
in experimental autoimmune encephalomyelitis or spinal cord
injury [2,6,8].
In the present study we have used a murine model of focal,
transient ischemia to investigate if 1) infused NC decrease ischemic
injury and restore brain function; 2) these cells induce changes in
the environment in which they are infused; 3) changes in brain
environment consequent to transient ischemia are relevant for NC
action.
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RESULTS
The experimental designs are illustrated in Fig. 1
Open field test
Seven days after ischemia mice receiving PBS icv (intracerebro-
ventricular) injection showed a significantly lower number of
rears and of contacts with objects indicating an impairment in
exploratory behavior and sensory-motor activity respectively, with
no change in inside (inversely related to anxious behaviour) and
outside crossings (related to motor activity). This deficit was
completely prevented in ischemic mice infused with NC 4 hours
after ischemia (NC(4 h)), but not in those infused with fibroblasts
that induced a non-significant improvement (Fig. 2A). In order to
understand if NC protective effect was persistent, in a further
experiment, ischemic mice receiving PBS or NC(4 h) were
exposed to the same test 14 days after ischemia. Similarly to what
observed at 1 week, ischemic mice infused with NC performed
significantly better compared to those injected with PBS. At
variance with these results, mice receiving NC 7 days after
ischemia (NC(7 d)) did not show any recovery of these impaired
functions (Fig. 3A)
Neuronal loss
The same experimental groups of ischemic mice observed in the
open field test were subsequently analyzed for the presence of
neurodegeneration. Striatum, the brain area corresponding to the
core of the lesion, and cortex, containing a portion of the lesion as
well as the penumbra, were considered. Seven days after ischemia,
neuronal loss (expressed as % of the contralateral) was 12.1062.00
in striatum and 7.661.15 in cortex (black columns in Fig. 2B). In
ischemic mice receiving NC(4 h) the neuronal loss was signifi-
cantly reduced in both areas, being 4.1462.46 (65.8% of
reduction) and 2.8460.83 (62.6% of reduction) in striatum and
cortex, respectively (grey columns in Fig. 2B). Neuronal loss was
not affected by fibroblast infusion (striped columns in Fig. 2B). We
then evaluated the neuronal loss 14 days after the ischemia and
Figure 1. Experimental design. NC were infused icv either 4 h (A) or
7 d (B) after ischemia. Histology, immunohistochemistry, confocal
microscopy, real time PCR, behavioural test and neuronal count
experiments were performed at the time points indicated.
doi:10.1371/journal.pone.0000373.g001
Figure 2. Open field test and neuronal loss in ischemic brain areas at day 7. Mice receiving NC(4 h) show a reversal of ischemia-induced
impairment in number of rears and objects, (A, n = 10) and a significant reduction in neuronal loss in striatum and cortex (B) compared to those
receiving PBS (n = 6). Fibroblast infusion 4 h after ischemia does not significantly affect open field impairment and neuronal loss (n = 7). Data are
expressed as mean6SEM. One-way ANOVA: (A) rears F: 6.122, p = 0.0002; (A) objects F: 16.10, p,0.0001; (B) striatum F: 17.67, p = 0.0002; (B) cortex F:
37.01, p,0.0001. Posthoc Tukey test: uu p,0.01, up,0.05 vs isch/PBS; ** p,0.01 *p,0.05 vs controls; 111 p,0.001 vs isch/NC(4 h).
doi:10.1371/journal.pone.0000373.g002
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found that the ischemic lesion was 24.1965.85 in striatum and
6.2961.88 in cortex of ischemic mice receiving PBS injections
(black columns in Fig. 3B), while in those infused with NC(4 h) it
was 6.7062.56 (72.3% of reduction) and 3.1261.45 (50.0% of
reduction), in striatum and cortex respectively (grey columns). In
mice receiving NC(7 d) the neuronal loss was not different from
those injected with saline, being 22.1162.91 in striatum and
6.7262.85 in cortex (striped columns in Fig. 3B).
Since volume changes could have affected the neuronal count
assessed by profile based method, a stereological assessment of
neuronal density was also performed in striatum (Fig. 4). The
hierarchical analysis of variance showed a significant effect for the
treatment (P = 0.02). The time effect was not significant as was the
interaction between time and treatment. The Bonferroni post-hoc
test showed significant differences among mean density differences
(and percentages) of the isch/NC(4 h) group and the isch/PBS,
isch/fibr and isch/NC(7 d) groups.
NC distribution and phenotype
We then analyzed NC presence and distribution in the brain of
ischemic and sham-operated mice 1, 7 and 14 days after surgery
(Fig. 5). One day after ischemia and NC(4 h) infusion (left panel in
Fig. 5), 5-CFDA (5-carboxy-di-O-acetylfluorescein) positive cells
were mostly located in the injected right ventricle (ipsilateral to the
lesion) and a few of them could be found in the left ventricle. Some
NC were juxtaposed to the ventricular walls both in the right and
in the left hemisphere, and some were already diffusing from the
Figure 3. Open field test and neuronal loss in ischemic brain areas at day 14. Mice receiving NC(4 h), but not those receiving NC(7 d) show
a reversal of ischemia-induced impairment in number of rears and objects (A, n = 10) and a significant reduction in neuronal loss in striatum and
cortex (B) compared to those receiving PBS (n = 6). Data are expressed as mean6SEM. One-way ANOVA: (A) rears F: 11.46, p,0.0001; (A) objects F:
5.38, p = 0.0056; (B) striatum F: 31.67, p,0.0001; (B) cortex F: 5.06, p = 0.0256. Posthoc Tukey test: uu p,0.01, up,0.05 vs isch/PBS, ** p,0.01, * p,0.05
vs controls; 111 p,0.001, 1 p,0.05 vs isch/NC(4 h).
doi:10.1371/journal.pone.0000373.g003
Figure 4. Box-plot of neuronal count performed in ischemic mice 7
and 14 days after ischemia with the optical dissector method.
Differences of neuronal density between contralateral and ipsilateral
striata are sorted by treatment and time. The box represents the
median and 25th–75th percentiles, whiskers represent the range, +
represents the mean of the group. The hierarchical ANOVA showed
a significant effect for the treatment (P = 0.02). The Bonferroni post-hoc
test showed significant differences (P,0.05) among mean density
differences of the isch/NC(4 h) group and the isch/PBS, isch/fibr and
isch/NC(7 d) groups. Data plotted have been multiplied by 16104.
doi:10.1371/journal.pone.0000373.g004
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ventricles into the striatum. A few NC were located along the icv
injection route. At day 7 the general distribution of NC was similar
to that observed at day 1 but the total number of NC was lower.
Fluorescent cells could be found heterogeneously dispersed in ipsi-
and contra- lateral brain areas. At day 14 only a few cells were still
present and could be observed in the ventral hippocampal
commissure (Fig. 5). At variance with ischemic, in sham-operated
mice few NC were present only at day 1, while at days 7 and 14 no
cells could be found in any of the 5 brains per time point analyzed
(right panel in Fig. 5). Similarly to what observed in sham-
operated mice, in ischemic mice infused with NC(7 d) only few
cells could be observed 1 day after infusion (day 8 from ischemia)
and no cells could be found at day 14 (n= 6). As mentioned above,
all the data on NC distribution have been obtained with 5-CFDA
fluorescent cells. Additionally, few mice per group have been
infused with Hoechst labeled NC, completely confirming the
results described above. Immunohistochemical evaluation dem-
onstrated that both at day 1 (Fig. 6) and at day 7 (data not shown),
most NC(4 h) were positive for nestin (a marker of neural stem
cells) and GFAP (Glial Fibrillary Acidic Protein, a marker for
astrocytes) and a few for NG-2 (a marker for oligodendrocyte
precursors). At day 14 neither nestin+, GFAP+ nor NG-2+ cell
could be observed (data not shown).
Gene expression
In order to evaluate possible changes induced in the ischemic
environment by NC infusion, at day 1 we analyzed the mRNA
expression of a few genes in the cortex of ischemic and sham-
Figure 5. Distribution of NC(4 h) in ischemic and sham-operated mice
at days 1, 7 and 14. NC were infused icv in the lesioned side. Drawings
represent typical results and are based on n=5 brains for each
experimental condition.
doi:10.1371/journal.pone.0000373.g005
Figure 6. Confocal analysis of immunoreactivity of NC(4 h) - green - and nestin, GFAP or NG-2 - red - at day 1. Colocalization (arrows) can be
observed between NC(4 h) and nestin, NC(4 h) and GFAP, NC(4 h) and NG-2. Images are taken in striatum, in proximity of the ventricular wall where
most cells can be found at this time point. Bar: 25 mm.
doi:10.1371/journal.pone.0000373.g006
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operated mice infused with NC(4 h) (Fig. 7). We first analyzed the
chemokine Stromal Derived Factor-1a (SDF-1a) and found that
ischemia significantly increased its expression. In ischemic mice
infused with NC its expression was further enhanced. No change
was observed in sham-operated mice infused with NC compared
with those infused with PBS. A similar pattern of expression was
found for the cytokine TGF-b1 and for the Vascular Endothelial
Growth Factor A (VEGF-A). In both cases ischemia activated their
expression and infusion of NC to ischemic mice was able to elicit
a higher increase. Ischemia induced a slight, non significant
decrease in the expression of Insulin Growth Factor-1 (IGF-1), but
ischemic mice receiving cell infusion showed a clear cut induction
of this gene. Lastly, Brain Derived Neurotrophic Factor (BDNF)
was significantly increased in ischemic mice infused with NC with
respect to controls (Fig. 7). A similar analysis of the same genes was
done in mice receiving NC(7 d), one day after NC infusion (8 days
after ischemia, see experimental design in Fig. 1B). None of these
genes was significantly activated in any experimental group.
Microglia/macrophages
Available antibodies (anti-CD11b) do not distinguish between
resident activated microglial cells and recruited macrophages, thus
the results obtained with immunohistochemistry provide informa-
tion on the degree of activation/recruitment of both these
inflammatory cells [9]. As expected, microglia/macrophages
became activated in ischemic mice. The maximal expression was
reached at day 7 (Fig. 8A). At each time point analyzed, in
ischemic mice receiving NC(4 h), the area occupied by CD11b
immunopositive cells measured in striatum was further increased.
Notably, such activation was neither present in sham-operated
mice infused with NC (Fig. 8A and B) nor in ischemic mice infused
with NC(7 d) (Fig. 8B). We then analyzed the interaction of
microglia/macrophages with the infused cells by confocal
microscopy. A high degree of colocalization of the markers for
both NC and microglia/macrophages was apparent at day 1 as
well as day 7 (Fig. 9). To get an insight into the functional meaning
of microglia/macrophage activation we explored their morphol-
ogy in more detail. We found that CD11b immunopositive cells
had a round shape exclusively in the ischemic area containing the
infused cells (Fig. 10A). CD11b+ microglia/macrophages appeared
to surround NC (Fig. 10C), and indeed were found to cap them
when observed at higher magnification (Fig. 10D). In the same
sections where this morphology was apparent, but in an area not
containing NC, CD11b+ cells showed a ramified morphology with
thin cell bodies, indicating that they were not activated (Fig. 10B).
DISCUSSION
Effectiveness of NC infusion
The first major finding of this study is the observation that NC(4 h)
revert functional deficits and counteract neurodegeneration in
ischemic mice. As early as one week after ischemia, the impair-
ment in exploratory behavior and sensory-motor activity observed
in ischemic mice was no more apparent in ischemic mice receiving
NC(4 h). This protective effect was observed also at day 14, as
assessed in independent experimental groups of mice. Also the
evaluation of the neuronal loss, both in striatum and in cortex,
confirmed the marked protective effect of NC. At both time points,
on day 7 and day 14, the neuronal cell count showed that ischemic
mice receiving NC(4 h) infusion were significantly protected.
Although several studies have addressed the issue of cell replace-
ment therapy in ischemic injury [3–5], to our best knowledge this
is the first study to show functional recovery and reversal of
Figure 7. mRNA expression of cytokines and trophic factors in ischemic cortex at day 1. Data are expressed as fold of induction compared to
sham/PBS group (mean6SEM, n = 6). Two-way ANOVA: SDF-1a F: 97.52, p,0.0001; TGF-b1 F: 31.54, p = 0.0001; VEGF-A F: 24.14, p = 0.0004; IGF-1 F:
28.21, p = 0.0002; BDNF F: 19.34, p = 0.0009. Posthoc Bonferroni test: **p,0.01, ***p,0.001 vs sham/PBS; uuup,0.001 vs isch/PBS; ### p,0.001 vs
sham/NC(4 h).
doi:10.1371/journal.pone.0000373.g007
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neurodegeneration by NC in ischemic injury.The choice of NC
has been a successful one. The infused cells include different stages
of multipotent stem cells. In specific in vitro conditions they are able
to differentiate into astrocytes, neurons and oligodendrocytes.
Following infusion in the brain, at day 1 and day 7, we observed
that most NC maintained their undifferentiated features being
mostly nestin+ and GFAP+, therefore indicating an abundance of
immature neurons and astrocytes, a few of them expressing
markers of oligodendrocyte precursors (NG-2+). In view of the
early recovery observed, we can exclude that NC(4 h) protective
effect was due to cell differentiation or replacement. We can
hypothesize that their protective action was due to a bystander
mechanism. The experiments discussed below elucidate their
possible protective mechanism.
Distribution and survival of NC in ischemic brain
tissue
We chose icv delivery of cells since it is less invasive, allows to
deliver more cells and produces more extensive cell seeding than
the local intraparenchymal injection. Moreover, compared to
systemic injections, icv delivery allows to infuse a lower number of
cells that are not dispersed in the whole body, but they are instead
concentrated where they are needed.From the injected ventricle,
NC rapidly diffused and migrated to several brain areas. At each
time point studied (days 1, 7, 14) NC(4 h) were mostly found in the
injected side, i.e. ipsilateral to the lesion. The comparison between
NC(4 h) distribution at different time points in ischemic and sham-
operated mice indicated that the ischemic environment affected
their survival in the brain tissue. In sham-operated mice, indeed,
the infused cells did not diffuse in the parenchyma and were
rapidly cleared out. Thus either molecules acting as attractant for
these cells or inhibiting their disposal are produced by the ischemic
environment. Similarly to what happened in sham-operated mice,
in ischemic mice infused with NC(7 d) the infused cells did not
persist in the brain tissue, but they were instead rapidly eliminated,
indicating that at this time point the ischemic environment has lost
its ability to promote NC survival. Another important issue derives
from the observation that even in ischemic mice NC were
progressively lost. It has been shown that the survival of stem cells
Figure 8. Quantification of microglia/macrophage activation. The
area occupied by CD11b immunopositive cells was measured in
striatum of sham-operated or ischemic mice receiving PBS, NC(4 h) or
NC(7 d) at different time points (see Experimental design, Fig. 1A and
B). Data are expressed as mean6SEM (n= 4–5). Two-way ANOVA: (A) F:
58.05, p,0.0001; (B) F: 10.19, p = 0.0002. Posthoc Bonferroni test:
*p,0.05, **p,0.01, ***p,0.001 vs sham/PBS; uup,0.01, uuup,0.001 vs
isch/PBS, ##p,0.01, ###p,0.001 vs sham/NC.
doi:10.1371/journal.pone.0000373.g008
Figure 9. Confocal analysis of immunoreactivity of NC (green) and microglia/macrophages (red). CD11b immunoreactivity signal, staining for
microglia/macrophages, colocalizes with that of NC(4 h) in striatum at day 1 (A–C) and 7 (D–F). Z- stacks are shown. Bar: 25 mm.
doi:10.1371/journal.pone.0000373.g009
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in brain tissue depends on several factors, including the type of cell
infused and its degree of differentiation. In agreement with our
observations, it was shown that multipotent neural stem cells,
(differently from lineage-restricted neural precursors) do not
survive in the intact CNS [10]. We show here that NC that do
not survive in sham-operated animals, can instead survive in the
ischemic brain tissue, although for a limited time. Notably this
period of time is long enough for them to exert a protective effect,
a condition that is almost ideal.
Gene expression
To explore the mechanism through which NC promote recovery
and to analyze the changes in the ischemic environment, we
assessed the mRNA expression of some protective factors. We
analyzed Stromal Derived Factor 1a (SDF-1a), a chemokine
produced by glial and endothelial cells in the injured brain that
binds the CXCR4 receptor expressed on NC and enhances their
proliferation and transmigration [11–14]. We then analyzed TGF-
b1, a pleiotropic cytokine involved in cell growth, differentiation
and tissue repair whose expression is induced in ischemic brain. Its
protective effects have been associated with ischemic tolerance
[15–17]. We also evaluated VEGF-A mRNA expression, an
angiogenic factor that undergoes transcriptional and posttran-
scriptional induction by hypoxia. It has been shown to exert acute
neuroprotective effects and to stimulate neurogenesis in ischemic
brain [18–20]. A specific role in promoting the survival of selected
NC subpopulation has recently been shown [21]. We then
analyzed IGF-1 a neurotrophic and anti-apoptotic factor known
to activate the survival PI3K-Akt pathways [22,23]. It is induced in
the injured brain although transient decrease in mRNA expres-
sion, similar to what we observed, has also been reported [24]. Its
expression is required for brain vascular remodeling [25]. In
a recent study IGF-1 has been identified as one of the upregulated
diffusible factors involved in promoting neural progenitor pro-
liferation after focal ischemia [26]. Finally, we assessed the
expression of BDNF, a neurotrophic factor provided with multiple
effects on brain plasticity that regulates neuronal survival, cell
migration and synaptic function [20,27]. The expression of all
these factors at day 1 was significantly enhanced in ischemic mice
receiving NC(4 h) compared to those receiving PBS. Thus
activation of all these trophic factors occurs maximally when NC
are infused into the ischemic brain. Notably, neither cell infusion
in sham-operated mice, nor that at day 7 from ischemia (NC(7 d))
elicited this response. Thus the reciprocal interaction between NC
and ischemic environment is crucial for the protective actions of
these cells.
Microglia/macrophages
Due to the lack of cellular markers that discriminate between
resident microglia and recruited macrophages, in this study we
refer to microglia/macrophages to designate cells immunoreactive
for CD11b, although most of them are probably likely to be typical
resident microglia. In a recent study on green fluorescent protein
transgenic bone marrow chimeric mice it was shown that the vast
majority of immunocompetent cells (iba-1+) present in the brain
tissue after transient middle cerebral artery occlusion (MCAO)
derives from resident microglia and that this cell type markedly
predominates and anticipates hematogeneous macrophages [28].
Our data show that NC(4 h) trigger an important activation of
microglia/macrophages, selectively in the ischemic tissue. Togeth-
er with recruited macrophages, resident microglial cells are the
major effectors of the brain immune response. During the process
of activation induced by a variety of stimuli (such as ischemia)
microglia proliferates, acquires dramatic changes in morphology,
expresses novel surface antigens and produces mediators that build
up and maintain the inflammatory response of the brain tissue
[29,30]. While microglia produces inflammatory cytokines,
chemokines, toxic molecules such as nitric oxide synthase,
arachidonic acid, reactive oxygen species and complement
proteins that contribute to the ischemic cell death, considerable
evidence now shows that resident microglia may also produce anti-
inflammatory and protective molecules, growth factors and
Figure 10. Morphology of microglia/macrophages (red). CD11b immunopositive cells at day 1 after ischemia and NC(4 h) infusion display a round,
phagocytic morphology in the injected (A) but not in the contralateral side were no NC are present (B). Microglia/macrophages appear to surround
NC as evidenced in C were NC are marked with Hoechst (blue). A further detail of the interaction between these cells is provided in D where one
microglia/macrophage appears to cap a NC (marked with 5-CFDA, green). Bar (A–C): 20 mm; bar (D): 7 mm.
doi:10.1371/journal.pone.0000373.g010
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neurotrophins, indicating that its activation may result in either
toxic or trofic effects [29,30]. Moreover, recent data show that
distinct subpopulations of microglial cells are activated by a CNS
injury [31]. These cellular subsets express selected antigens that
may subserve different roles including repair and recovery from
injury. Our data strongly suggest that activation of microglia/
macrophages is required for NC action. In fact NC(4 h), but not
NC(7 d) or NC infused to sham-operated mice, are effective in
protecting from ischemic injury and induce a more marked
microglia/macrophage activation. Consistent with this observa-
tion, previous data in the literature indicate that the brain
inflammatory response is relevant for stem cell survival and action
[3,8,32].Our data also show other aspects of the complex
interaction between NC and microglia/macrophages that appear
to be engaged in a close physical reciprocal contact. This
interaction resembled what has been previously described as
‘‘capping’’ of the NC by amoeboid microglia [33]. It is possible
that this cell-cell contact is related to microglia/macrophage
phagocytic activity. If this is the case, it could be speculated that
the progressive disappearance of NC from the brain from day 1 to
14 results from such phagocytic action. Thus, microglia-induced
cell death in the early hours that follow brain ischemia may be
regarded as a protective mechanism against further secondary
damage that could ‘‘prime’’ the damaged regions for later
regeneration [34].Several in vitro studies have shown that microglia
does not constitute a uniform population but it rather includes
different cell types that can develop a braod range of functional
phenotypes [35]. Our in vivo data support this view indicating that
ischemia-activated microglia can on one hand contribute to
rescuing the damaged tissue. We can speculate that microglia may
trigger or contribute to the production of trophic factors and
protective cytokines. On the other hand microglia may get rid of
infused cells by a typical phagocytic acitivity implying a NC-
microglia cell contact.
Conclusions
NC, administered 4 h after transient focal ischemia, effectively
counteracted the ischemia/reperfusion injury in an in vivo animal
model of MCAO. Namely NC reverted both functional impair-
ments evaluated by testing for exploratory behavior and sensory-
motor activity, and decreased neuronal loss. Several lines of
evidence indicate that the reciprocal interaction between NC and
the ischemic environment is crucial for NC protective actions.
First, NC survival in the brain tissue is enhanced by the ischemic
environment. Second, NC induce the activation of chemokine,
angiogenic and neurotrophic factor transcripts early after injury.
Third, NC protective effect relates to microglia/macrophages
activation. Thus, NC can promote protective effects in ischemia/
reperfusion injury by modifying the ischemic environment via
induction of trophic factors and activation of selected aspects of the
inflammatory response. Based on these results we propose that
a bystander control of the ischemic environment may be the
mechanism used by NC to rapidly restore acutely injured brain
function.
MATERIALS AND METHODS
Animals
Male C57BL/6 (26–28 g, 11–12 weeks of age, Charles River,
Calco, Italy) were housed 5 per cage and kept at constant
temperature (2161uC) and relative humidity (60%) with regular
light/dark schedule (7 am–7 pm). Food (Altromin pellets for mice)
and water were available ad libitum. Procedures involving animals
and their care were conducted in conformity with institutional
guidelines that are in compliance with national (D.L. n.116, G.U.
suppl. 40, 18 February 1992) and international laws and policies
for animal care (EEC Council Directive 86/609, OJ L 358,1;
Dec.12, 1987; NIH Guide for the Care and Use of Laboratory
Animals, U.S. National Research Council 1996).
Isolation and culture of NC
As previously described [6,7,36,37], brains of newborn mice were
removed and placed in PBS containing penicillin and streptomy-
cin (GIBCO, Paisley, Scotland, UK). Brain tissue was mechani-
cally triturated with a fire-polished Pasteur pipette. The tissue
suspension was collected and treated with collagenase type I (0.5%
BSA, 0.1% collagenase in PBS w/o Ca2+ and Mg2+, GIBCO,
Paisley, Scotland, UK) and DNAse Type I (1 U/mL, USBiolo-
gical/DBA, Segrate, Italy) for 30–45 minutes at 37uC in
a humidified atmosphere containing 5% CO2. After centrifuga-
tion, pellets were plated in culture flasks in the presence of 20 ng/
ml human recombinant EGF and bFGF in basal serum-free
medium optimized for neural stem cell growth [6,36]. Neuro-
spheres formed within 7 days were harvested and dissociated to
single cells with collagenase and replated twice under the same
conditions described above. Bulk cultures were generated by
passing the cells at higher density in the same growth medium
every 10 days. Cells for transplantations were used starting from 7
passages. After dissociation, cell count and viability test were
assessed by trypan blue exclusion.
Foetal fibroblast culture
A commercially available cell line of murine foetal fibroblasts
(NIH 3T3) was used as negative control since they are not derived
from CNS. Fibroblasts were cultured in Dulbecco’s modified
Eagle’s medium with 4 mM L-glutamine containing 1.5 g/L
sodium bicarbonate and 4.5 g/L glucose and 10% of bovine calf
serum (all Gibco, OR, USA) at 37uC degrees and 5% CO2 in an
humidified atmosphere. When the cell layer reached the 80% of
confluence, cells were washed with PBS and 2.0 to 3.0 ml of
Trypsin-EDTA solution was added to each flask. Cells were
observed under an inverted microscope until cell layer was
dispersed. Complete growth medium (6.0 to 8.0 ml) was added in
order to block the trypsin–EDTA effects and cells were aspirated
by gently pipetting. After a brief centrifugation cells were
resuspended in 3–5 ml of PBS with Dnase.
5-CFDA and Hoechst staining
Before infusion, NC were labelled with fluorescent dyes for in vivo
tracing. Cells were exposed to 7.5 mM green fluorescent dye 5-
CFDA (Vybrant SE Cell Tracer kit V-12883, Molecular Probes,
Eugene, OR, USA) for 15 min at 37uC in a humidified
atmosphere containing 5% CO2 and then resuspended in PBS
without calcium and magnesium. Alternatively, they were stained
with 10 mg/mL Hoechst 33258 (2,3 bis-benzimide, Sigma, Mo,
USA) for 1 h at 37uC in their culture medium and subsequently
resuspended in PBS without calcium and magnesium. In both
cases, the absolute number of cells was evaluated by light
microscopy. Vitality of NC after fluorescent staining was evaluated
in each experiment by trypan blue exclusion test.
Transient focal cerebral ischemia
Ischemia was achieved by intraluminal model of MCAO as
previously described [9,38,39]. To confirm the adequacy of the
vascular occlusion in each animal, blood flow was measured by
laser Doppler flowmetry (Transonic BLF-21) using a flexible
0.5 mm fiberoptic probe (Transonic, Type M, 0.5 mm diameter)
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positioned on the brain surface in the MCA territory and secured
with impression material on the skull at the following stereotaxic
coordinates: AP=21 mm; L=23.5 mm. The filament was
advanced in the MCA until a .70% reduction of pre-ischemic
blood flow was observed. At the end of a 30 min ischemic period,
blood flow was restored by carefully removing the nylon filament.
During surgery mice were maintained at constant temperature
(37+/20.5uC) using a heathing pad equipped with a rectal probe
(LSI-Letica Spain). Sham-operated mice were also prepared as
previously described [9,38,39].
NC and fibroblast administration
NC (56105 in PBS) were infused icv either 4 hours (NC(4 h)) or 7
days (NC(7 d)) after the end of MCAO (Fig. 1) in a volume of 5 ml
over 10 minutes, using an automatic micropump (CMA, Carnegie
Medicine, Sweden) in anesthetized mice (0 mm caudal to bregma,
21 mm lateral to the midline and 23 mm beneath the dura mater)
[40]. The needle was left in place afterwards for additional
5 minutes. Fibroblasts (56105 in PBS) were infused 4 hours after
the end of MCAO following the same procedure.
Open field test
Behavior was evaluated in an open field paradigm [41,42], delivered
once to each mouse, 7 or 14 days after ischemia/reperfusion. During
5 min observation the number of inner squares crossed and that of
outer squares crossed, the number of rearings, except those for
grooming, and the number of contacts with the objects were counted
by an investigator blinded to the treatment.
Neuronal count: profile based method
Brain sections obtained from perfused brains were mounted on
slides and were stained with Cresyl Violet. Neurons were counted
as described previously [43]. Briefly, for each mouse three coronal
sections, corresponding to +0.30, 20.30 and 20.70 mm from
bregma, were considered and neurons in striatum and in cortex
were counted separately. An Olympus BX61 microscope, inter-
faced with Soft Imaging System Colorview video camera and
AnalySIS software (all Olympus Tokyo, Japan) was used. The
degree of neuronal loss was calculated by pooling the number of
stained neurons in the sections of each hemisphere and was
expressed as percentage of the contralateral hemisphere. The
analysis was performed by an investigator blinded to the
treatment.
In a previous study we have shown that the lesion protocol used
results in a neuronal loss of 14.0+/22.2% measured in striatum at
day 7 and corresponds to a lesion volume of 12.11+/21.44 mm3
measured at day 1. Actually it should be noted that seven days
after ischemia the lesioned area cannot be precisely assessed by the
paleness of the tissue following neutral red, cresyl violet or similar
staining because of the large microglial activation and cell
recruitment to the lesion site. This is why at this time point, the
ischemic lesion is assessed by neuronal count [17].
Stereological estimation of the neuronal density
Neurodegeneration in striatum was assessed also by the optical
dissector method using the StereoInvestigator program (Micro-
brightfield Inc.) and the Zeiss Imager microscope with a motorized
XY stage and focus. The image of the field view was transferred on
the computer monitor using an Optronics Magnifire camera. For
each striatum 3 sections chosen systematically (coordinates: +0.30,
20.30 and 20.70 mm from bregma, respectively) were used to
assess the non biased density. The section contour was digitized
using a cursor at low magnification (2.56) and was fractionated in
counting frames of 2506300 mm. At high magnification (1006)
boxes of 50650620 mm were used to count the neurons inside
each frame. The frames were scanned systematically under
program supervision starting with a randomly chosen frame.
The neurons present in the top reference section and absent in the
bottom lookup section were counted as tops. More than 500 tops
were counted for each striatum. The density was estimated from
the total number of tops counted in the striatum divided by the
total volume of counting boxes.
The statistical analysis was carried out using the SAS software
package (SAS Institute Inc., Cary, NC, USA). The distribution of
measurements was tested for normality. The general linear model
(GLM) procedure was applied to test the treatment (the following
groups were considered: isch/PBS, isch/fibr, isch/NC(4 h), isch/
NC(7 d)) and time (7 d and 14 d) effect, using a hierarchical two
way analysis of variance model. Then a post-hoc Bonferroni test
was used to assess the difference between groups mean at P,0.05.
Immunohistochemistry
Immunohistochemistry was performed applying standard proto-
cols. The primary antibodies used were: monoclonal anti-GFAP
(1:2000), anti-Nestin (1:1000), anti-NG-2 (1:200) (all antibodies
from Chemicon International, CA), anti-CD11b (1:300, a kind
gift of Dr. A. Doni, Mario Negri Institute, Milan, Italy). The
secondary antibodies were: Alexa 555 fluoro-conjugated goat anti-
mouse IgG for nestin and GFAP or Alexa 594 fluoro-conjugated
goat anti-rat IgG for CD11b and goat anti-rabbit IgG for NG-2
(all Molecular Probes, OR). Microglia/macrophages activation
was revealed by reaction with 3,3 diaminobenzidine tetrahy-
drochloride (DAB, Vector laboratories, CA) as previously de-
scribed [43]. Immunopositive cells were evaluated in striatum by
an image analysis software (AnalySIS, Olympus Tokyo, Japan).
For each mouse, 3 sections, corresponding to coordinates
21.10 mm, 20.70 mm and 20.20 mm from bregma, were
considered. In each slice, 6 fields at 206 were analyzed. Results
are expressed as ratio between immunostained area and the total
area of the fields assessed (100%).
Table 1. Primers used for quantitative real-time polymerase
chain reaction analysis of SDF-1a, BDNF, IGF-1, VEGF-A, TGF-
b1, b-actin transcript levels.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
cDNA Sequence (59 to 39) Amplified region
SDF-1a GATTGTTGCACGGCTGAAGA (fwda) 255–305
NM013655 TTCGGGTCAATGCACACTTG (revb)
BDNF AGGCACTGGAACTCGCAATG (fwda) 1271–1321
NM007540 AAGGGCCCGAACATACGATT (revb)
IGF-1 TGGAGATGTACTGTGCCCCA (fwda) 1609–1659
NM184052 GGATAGAGCGGGCTGCTTTT (revb)
VEGF-A CCTGCAAAAACACAGACTCGC (fwda) 882–932
NM009505 CGTTTAACTCAAGCTGCCTCG (revb)
TGF-b1 CCAAGGAGACGGAATACAGGG (fwda) 1494–1544
NM011577 TCACAAGAGCAGTGAGCGCT (revb)
b-actin GCCCTGAGGCTCTTTTCCAG (fwda) 850–900
NM007393 TGCCACAGGATTCCATACCC (revb)
aforward
breverse
doi:10.1371/journal.pone.0000373.t001..
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Confocal analysis
Immunofluorescent staining was acquired by an Olympus BX61
microscope equipped with an Olympus confocal scan unit FV500
equipped with two laser lines, Ar-Kr green (488 nm) and He-Ne
red (646 nm) used to detect the NC marker, 5-CFDA, and
secondary antibodies conjugated at Alexa 555, respectively.
Colocalization was revealed using a scanning sequential mode to
eliminate possible bleed-through effect. The system was managed
by Fluoview software (Olympus Tokyo, Japan)
RNA isolation, cDNA synthesis and real-time PCR
At day 1 or 8 mice were sacrificed for gene expression analysis.
Brains were rapidly removed and lesioned side cortex dissected
and frozen on dry ice. Total RNA was obtained from tissue
specimen using the Trizol reagent (Gibco BRL, MD) [9,44].
Samples of total RNA (1.5 mg) were reverse transcripted with
random hexamer primers using Multi-Scribe Reverse Transcrip-
tase (TaqMan Reverse transcription reagents, Applied Biosystems,
Foster City, CA). Real-time PCR was conducted according to
manifacturer instructions [9,44]. b-actin was used as reference
gene and relative gene expression levels were determined
according to manufacturer’s DDCt method (Applied Biosystems).
Primers were designed using Primer Express 2.0 software (Applied
Biosystems, Foster City, CA) based on GenBank accession
numbers (Table 1).
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